CD274 and neoplasm: We aimed at detecting, in a prospective trial, if clinical factors or tumor biomarkers analyzed in the primary tumor before starting treatment (HIV, HPV, PD-L1, Ki-67, and DNA tumor mutations) were associated with CRT efficacy.